As Eli Lilly, compounders battle over obesity drugs, patients are caught in the middle

Experts fear some patients may turn to dangerous alternatives if weight loss drug shortages persist

October 11, 2024 Check out STAT+

Sponsored By

Adobe As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle The FDA's warning to compounders threatens access to cheaper versions of Zepbound and Lilly's diabetes medicine Mounjaro. By Elaine Chen STAT+ | John Maraganore on his new biotech venture, R&D vivacity and Nobel award-winning AI The former CEO of Alnylam spoke with STAT about raising money to focus on one big idea, and the prospect for a $100 billion Alnylam. By Allison DeAngelis and Adam Feuerstein STAT+ | Teva agrees to pay $450 million to settle kickback and price-fixing allegations Teva also agreed to pay $25 million to resolve allegations it conspired with other generic drug companies to fix prices for three drugs. By Ed Silverman JONATHAN NACKSTRAND/AFP via Getty Images STAT+ | Nobel-winning AI was built on open science. Will the quest for profits quash collaboration? The chemistry prize shows the power of collective research, freely shared. Now some worry data access will be restricted as commercialization grows By Katie Palmer and Brittany Trang Crypto for CRISPR, a new RNAi startup, & a Nobel for AI On The Readout LOUD, John Maraganore discusses his new startup, and STAT's Megan Molteni tells the latest about "CRISPR baby" scientist He Jiankui. By Allison DeAngelis and Adam Feuerstein A setback for the Denali-Sanofi partnership Today's biotech news update includes Sarepta stock tanking, a setback for Denali and Sanofi's partnership, and Novo's Catalent purchase. By Meghana Keshavan Adobe Men won all the science Nobels this year. There's an even bigger problem All seven Nobel Prize laureates in science in 2024 were men, reflecting the larger problem of gender bias in the sciences. By Anil Oza

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser